TY - JOUR
T1 - Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010
T2 - General view of the pathogens' antibacterial susceptibility
AU - Yanagihara, Katsunori
AU - Kadota, Junichi
AU - Aoki, Nobuki
AU - Matsumoto, Tetsuya
AU - Yoshida, Masaki
AU - Yagisawa, Morimasa
AU - Oguri, Toyoko
AU - Sato, Junko
AU - Ogasawara, Kazuhiko
AU - Wakamura, Tomotaro
AU - Sunakawa, Keisuke
AU - Watanabe, Akira
AU - Iwata, Satoshi
AU - Kaku, Mitsuo
AU - Hanaki, Hideaki
AU - Ohsaki, Yoshinobu
AU - Watari, Tomohisa
AU - Toyoshima, Eri
AU - Takeuchi, Kenichi
AU - Shiokoshi, Mayumi
AU - Takeda, Hiroaki
AU - Miki, Makoto
AU - Kumagai, Toshio
AU - Nakanowatari, Susumu
AU - Takahashi, Hiroshi
AU - Utagawa, Mutsuko
AU - Nishiya, Hajime
AU - Kawakami, Sayoko
AU - Kobayashi, Nobuyuki
AU - Takasaki, Jin
AU - Mezaki, Kazuhisa
AU - Konosaki, Hisami
AU - Aoki, Yasuko
AU - Yamamoto, Yumiko
AU - Shoji, Michi
AU - Goto, Hajime
AU - Saraya, Takeshi
AU - Kurai, Daisuke
AU - Okazaki, Mitsuhiro
AU - Niki, Yoshihito
AU - Yoshida, Koichiro
AU - Kawana, Akihiko
AU - Saionji, Katsu
AU - Fujikura, Yuji
AU - Miyazawa, Naoki
AU - Kudo, Makoto
AU - Sato, Yoshimi
AU - Yamamoto, Masaki
AU - Yoshida, Takashi
AU - Nakamura, Masahiko
AU - Tsukada, Hiroki
AU - Imai, Yumiko
AU - Tsukada, Ayami
AU - Kawasaki, Satoshi
AU - Honma, Yasuo
AU - Yamamoto, Toshinobu
AU - Ban, Nobuyoshi
AU - Mikamo, Hiroshige
AU - Sawamura, Haruki
AU - Miyara, Takayuki
AU - Toda, Hirofumi
AU - Sato, Kaori
AU - Nakamura, Tadahiro
AU - Fujikawa, Yasunori
AU - Mitsuno, Noriko
AU - Mikasa, Keiichi
AU - Kasahara, Kei
AU - Sano, Reiko
AU - Sugimoto, Keisuke
AU - Asari, Seishi
AU - Nishi, Isao
AU - Toyokawa, Masahiro
AU - Miyashita, Naoyuki
AU - Koguchi, Yutaka
AU - Kusano, Nobuchika
AU - Mihara, Eiichirou
AU - Kuwabara, Masao
AU - Watanabe, Yaeko
AU - Kawasaki, Yuji
AU - Takeda, Kenichi
AU - Tokuyasu, Hirokazu
AU - Masui, Kayoko
AU - Negayama, Kiyoshi
AU - Hiramatsu, Kazufumi
AU - Aoki, Yosuke
AU - Fukuoka, Mami
AU - Magarifuchi, Hiroki
AU - Nagasawa, Zenzo
AU - Suga, Moritaka
AU - Muranaka, Hiroyuki
AU - Morinaga, Yoshitomo
AU - Honda, Junichi
AU - Fujita, Masaki
N1 - Funding Information:
This investigation was supported by grants from following pharmaceutical companies (alphabetical order): Astellas Pharma Inc.,, Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Glaxo SmithKline K.K., Kyorin Pharmaceutical Co., Ltd., Maruho Co.,Ltd., Meiji Seika Pharma Co., Ltd., MSD K.K., Pfizer Japan Inc., Sanofi-Aventis K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Toyama Chemical Co., Ltd.
Funding Information:
Katsunori Yanagihara has received speaker's honorarium from Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co.,Ltd., Astellas Pharma Inc. and MSD K.K., donation from Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co.,Ltd. and MSD K.K. and supported, in part, by a fund from Pfizer Japan Inc. and Taisho Toyama Pharmaceutical Co.,Ltd. Junichi Kadota has received speaker's honorarium from Taisho Toyama Pharmaceutical Co.,Ltd., Pfizer Japan Inc., MSD K.K., Kyorin Pharmaceutical Co.,Ltd., Daiichi Sankyo Co., Ltd., Glaxo SmithKline K.K., payments for a manuscript drafting and edting from Nankodo Co., Ltd. and donation from Astellas Pharma Inc. Nobuki Aoki has received speaker's honorarium from Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co.,Ltd., Kyorin Pharmaceutical Co., Ltd. and Bayer Yakuhin, Ltd. Tetsuya Matsumoto has received speaker's honorarium from Pfizer Japan Inc., Meiji Seika Pharma Co., Ltd. and MSD K.K. Masaki Yoshida is a consultant of Astellas Pharma Inc. Keisuke Sunakawa has received speaker's honorarium from Taisho Toyama Pharmaceutical Co.,Ltd. and Meiji Seika Pharma Co., Ltd. Akira Watanabe has received speaker's honorarium from MSD K.K., Glaxo SmithKline K.K., Shionogi & Co., Ltd., Daiichi Sankyo Co.,Ltd., Taisho Toyama Pharmaceutical Co., Ltd. and Pfizer Japan Inc.; grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taisho Pharmaceutical Co.,Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taiho Pharmaceutical Co.,Ltd. and Meiji Seika Pharma Co., Ltd. Satoshi Iwata has received speaker's honorarium from Astellas Pharma Inc., Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co.,Ltd., MSD K.K., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd. and Japan Vaccine Co., Ltd., donation from Taisho Toyama Pharmaceutical Co.,Ltd. and supported, in part, by a fund from Nikon Corporation. Mitsuo Kaku has received speaker's honorarium from Taisho Toyama Pharmaceutical Co.,Ltd., Shionogi & Co., Ltd., Pfizer Japan Inc. and Sumitomo Dainippon Pharma Co., Ltd. and donation from Astellas Pharma Inc. Hideaki Hanaki is a member of a laboratory endowed chair from Kohjin Bio Co.,Ltd. Yoshihito Niki has received a speaker's honorarium from Astellas Pharma Inc., MSD K.K., Glaxo SmithKline K.K., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., and Pfizer Japan Inc.; and grant support from Astellas Pharma Inc., Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd, Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma, MSD K.K., Teva Pharma Japan Inc. Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation and Meiji Seika Pharma Co., Ltd. Koichiro Yoshida has received speaker's honorarium from Janssen Pharmaceutical K.K. and Astellas Pharma Inc. Hiroki Tsukada has received speaker's honorarium from Taisho Toyama Pharmaceutical Co.,Ltd.
Publisher Copyright:
© 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from patients in Japan, was conducted by Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases and Japanese Society for Clinical Microbiology in 2010.The isolates were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections during the period from January and April 2010 by three societies. Antimicrobial susceptibility testing was conducted at the central reference laboratory according to the method recommended by Clinical and Laboratory Standard Institutes using maximum 45 antibacterial agents.Susceptibility testing was evaluable with 954 strains (206 Staphylococcus aureus, 189 Streptococcus pneumoniae, 4 Streptococcus pyogenes, 182 Haemophilus influenzae, 74 Moraxella catarrhalis, 139 Klebsiella pneumoniae and 160 Pseudomonas aeruginosa). Ratio of methicillin-resistant S.aureus was as high as 50.5%, and those of penicillin-intermediate and -resistant S.pneumoniae were 1.1% and 0.0%, respectively. Among H.influenzae, 17.6% of them were found to be β-lactamase-non-producing ampicillin (ABPC)-intermediately resistant, 33.5% to be β-lactamase-non-producing ABPC-resistant and 11.0% to be β-lactamase-producing ABPC-resistant strains. Extended spectrum β-lactamase-producing K.pneumoniae and multi-drug resistant P.aeruginosa with metallo β-lactamase were 2.9% and 0.6%, respectively.Continuous national surveillance of antimicrobial susceptibility of respiratory pathogens is crucial in order to monitor changing patterns of susceptibility and to be able to update treatment recommendations on a regular basis.
AB - The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from patients in Japan, was conducted by Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases and Japanese Society for Clinical Microbiology in 2010.The isolates were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections during the period from January and April 2010 by three societies. Antimicrobial susceptibility testing was conducted at the central reference laboratory according to the method recommended by Clinical and Laboratory Standard Institutes using maximum 45 antibacterial agents.Susceptibility testing was evaluable with 954 strains (206 Staphylococcus aureus, 189 Streptococcus pneumoniae, 4 Streptococcus pyogenes, 182 Haemophilus influenzae, 74 Moraxella catarrhalis, 139 Klebsiella pneumoniae and 160 Pseudomonas aeruginosa). Ratio of methicillin-resistant S.aureus was as high as 50.5%, and those of penicillin-intermediate and -resistant S.pneumoniae were 1.1% and 0.0%, respectively. Among H.influenzae, 17.6% of them were found to be β-lactamase-non-producing ampicillin (ABPC)-intermediately resistant, 33.5% to be β-lactamase-non-producing ABPC-resistant and 11.0% to be β-lactamase-producing ABPC-resistant strains. Extended spectrum β-lactamase-producing K.pneumoniae and multi-drug resistant P.aeruginosa with metallo β-lactamase were 2.9% and 0.6%, respectively.Continuous national surveillance of antimicrobial susceptibility of respiratory pathogens is crucial in order to monitor changing patterns of susceptibility and to be able to update treatment recommendations on a regular basis.
KW - Resistance
KW - Respiratory tract infection
KW - Surveillance
KW - Susceptibility
UR - http://www.scopus.com/inward/record.url?scp=84939989425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939989425&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2015.02.008
DO - 10.1016/j.jiac.2015.02.008
M3 - Article
C2 - 25817352
AN - SCOPUS:84939989425
SN - 1341-321X
VL - 21
SP - 410
EP - 420
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 6
ER -